Trial reportThe journal of nutrition, health & aging2009
Trospium and cognition in patients with late onset Alzheimer disease.
Trial report in The journal of nutrition, health & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- A systematic review of neurocognitive dysfunction with overactive bladder medications.International urogynecology journal · 2021Pooled it
- Brain Over Bladder: A Systematic Review of Dual Cholinesterase Inhibitor and Urinary Anticholinergic Use.Drugs & aging · 2018Pooled it
- Trospium Chloride in the Treatment of Overactive Bladder Syndrome and Detrusor Overactivity.Advances in therapy · 2025Review
- Voiding Phase Dysfunction in Multiple Sclerosis: Contemporary Review of Terminology, Diagnosis, Management, and Future Directions.The Urologic clinics of North America · 2024Review
- The cognitive effect of anticholinergics for patients with overactive bladder.Nature reviews. Urology · 2021Review
- Neurogenic Bladder: Epidemiology, Diagnosis, and Management.Seminars in neurology · 2020Review
- Overactive Bladder in Frail Older Adults.Drugs & aging · 2020Review
- Article
- The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis.Current neurology and neuroscience reports · 2018Review
- Frequency and coincidence of geriatric syndromes according to age groups: single-center experience in Turkey between 2013 and 2017.Clinical interventions in aging · 2018Article
- CUA guideline on adult overactive bladder.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017Article
- Treatment Options for Urogenital Dysfunction in Parkinson's Disease.Current treatment options in neurology · 2016Review
- Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations.Drugs & aging · 2015Review
- Effect of galantamine on platelet functions in healthy elderly people.The Indian journal of medical research · 2013Article
- Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.Drugs & aging · 2012Review
- Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Drug safety · 2011Review
- Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.International urogynecology journal · 2011Review
- Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?Movement disorders clinical practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCholinesterase inhibitors for the treatment of Alzheimer's Disease (AD) and antimuscarinic agents for the treatment of urge urinary incontinence (UUI) may reduce the potential effect of each other in the patients with both diseases. Trospium has a relatively low lipophilicity and low CNS penetration, and galantamine, a cholinesterase inhibitors, has also allosterically modulates nicotinic cholinergic receptors. This study was designed to evaluate the effects of dual use of trospium and galantamine for 6 months in the elderly patients with AD and UUI. SETTING/
participantsOne hundred and seventy eight elderly patients: 99 UUI patients (Group I, treated with trospium), 43 AD patients (Group II, treated with galantamine) and 36 AD and UUI patients (Group III, treated with galantamine and trospium) were evaluated by geriatric assessments, the Global Perception Index (GPI), Patients' Satisfaction Question (PSQ), Estimated Patients' Improvement (EPI), nocturia and pads/day at baseline and in the 6th month.
resultsTrospium increased the satisfaction of the patients in Groups I and III according to the EPI, PSQ, GPI, number of nocturia and pads/day. Decreasing in the GDS score was significant in the Group I and III (p < 0.05). Decreasing in the ADL score was significant in the Group III (p < 0.05). The MMSE scores were not significantly changed in the all groups during the 6 months.
conclusionConsequently, we have thought that a combination of trospium and galantamine could be recommended for the management of the elderly patients with UUI and AD, which are common problems in the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.